Dicyclomine
drugOn this page
Also known as DicicloverinaDicycloverineDicymineKolantylDicycloverinSID11111098SID11112188SID90341021SID50100226SID50104289SID144207120SID170464896DICYCLOMINE HYDROCHLORIDE
Summary
Dicyclomine (CHEMBL1123) is an approved small-molecule muscarinic antagonist (ATC A03AA07) targeting CHRM1, CHRM2, and CHRM3; indicated across 1 condition.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: A03AA07
- Targets: 4 (CHRM1, CHRM2, CHRM3…)
- Indications: 1 condition
- Chemistry: 309.5 Da · C19H35NO2
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1123 |
| Name | Dicyclomine |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | yes |
| PubChem CID | 3042 |
| ChEBI | CHEBI:4514 |
| ATC | A03AA07 |
| Molecular formula | C19H35NO2 |
| Molecular weight | 309.5 |
| InChIKey | CURUTKGFNZGFSE-UHFFFAOYSA-N |
SMILES: CCN(CC)CCOC(=O)C1(CCCCC1)C2CCCCC2
IUPAC name: 2-(diethylamino)ethyl 1-cyclohexylcyclohexane-1-carboxylate
ChEBI definition: The ester resulting from the formal condensation of 1-cyclohexylcyclohexanecarboxylic acid with 2-(diethylamino)ethanol. An anticholinergic, it is used as the hydrochloride to treat or prevent spasm in the muscles of the gastrointestinal tract, particularly that associated with irritable bowel syndrome.
Pharmacological roles (ChEBI): muscarinic antagonist, antispasmodic drug, parasympatholytic.
Also known as: Dicicloverina, Dicycloverine, Dicymine, Kolantyl, Dicycloverin, SID11111098, SID11112188, SID90341021, SID50100226, SID50104289, Dicyclomine, dicyclomine
Parent form; salt/anhydrous children: CHEMBL1200479
Patent coverage: 2,515 distinct patent families (8,691 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).
| Gene | Target | Action | pAffinity | Cancer dependency | UniProt |
|---|---|---|---|---|---|
| CHRM1 | M1 receptor | Antagonist | 9.08 | 0.2% | P11229 |
| CHRM2 | M2 receptor | Antagonist | 6.6 | 0% | P08172 |
| CHRM3 | M3 receptor | Antagonist | 9.03 | 0% | P20309 |
| CHRM4 | M4 receptor | Antagonist | 8.3 | 1.6% | P08173 |
Broader ChEMBL bioactivity targets: 28 (assay-derived). Sample: Prelamin-A/C, Thrombopoietin, Muscarinic acetylcholine receptor M4, 5-hydroxytryptamine receptor 2B, Histamine H2 receptor, Thyrotropin receptor, Muscarinic acetylcholine receptor M5, D(1A) dopamine receptor, Sodium channel alpha subunits; brain (Types I, II, III), Muscarinic acetylcholine receptor M2.
Bioactivity
ChEMBL activities: 53 potent at pChembl ≥ 5 of 64 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| CHRM4 | 9.39 | Ki | 0.41 | nM | CHEMBL_ACT_7691880 |
| CHRM1 | 9.08 | Ki | 0.83 | nM | CHEMBL_ACT_7691874 |
| CHRM3 | 9.03 | Ki | 0.93 | nM | CHEMBL_ACT_7691878 |
| CHRM5 | 8.77 | Ki | 1.71 | nM | CHEMBL_ACT_7691882 |
| SIGMAR1 | 8.69 | Ki | 2.06 | nM | CHEMBL_ACT_7693985 |
| CHRM5 | 8.62 | IC50 | 2.38 | nM | CHEMBL_ACT_7691881 |
| P08482 | 8.61 | Ki | 2.47 | nM | CHEMBL_ACT_249974 |
| CHRM4 | 8.53 | IC50 | 2.95 | nM | CHEMBL_ACT_7691879 |
| CHRM1 | 8.46 | IC50 | 3.46 | nM | CHEMBL_ACT_7691873 |
| CHRM3 | 8.36 | IC50 | 4.38 | nM | CHEMBL_ACT_7691877 |
| SIGMAR1 | 8.31 | IC50 | 4.89 | nM | CHEMBL_ACT_7693984 |
| CHRM1 | 8.04 | AC50 | 9.1 | nM | CHEMBL_ACT_25210742 |
| CHRM2 | 7.8 | Ki | 16 | nM | CHEMBL_ACT_7691876 |
| CHRM1 | 7.76 | AC50 | 17.4 | nM | CHEMBL_ACT_25210788 |
| P08482 | 7.45 | Potency | 35.5 | nM | CHEMBL_ACT_4807361 |
| CHRM2 | 7.34 | IC50 | 46 | nM | CHEMBL_ACT_7691875 |
| P10980 | 7.33 | Ki | 47.3 | nM | CHEMBL_ACT_249975 |
| CHRM1 | 7.23 | AC50 | 59 | nM | CHEMBL_ACT_25136154 |
| HTR2A | 7.16 | Ki | 69 | nM | CHEMBL_ACT_7691956 |
| LMNA | 7.15 | Potency | 70.8 | nM | CHEMBL_ACT_3664113 |
| P08482 | 6.95 | Potency | 112.2 | nM | CHEMBL_ACT_4853968 |
| CHRM3 | 6.92 | AC50 | 120 | nM | CHEMBL_ACT_25137352 |
| HTR2A | 6.62 | IC50 | 240 | nM | CHEMBL_ACT_7691955 |
| HTR2C | 6.61 | Ki | 245 | nM | CHEMBL_ACT_7693975 |
| DRD3 | 6.39 | Ki | 411 | nM | CHEMBL_ACT_7689811 |
| HTR2C | 6.33 | IC50 | 468 | nM | CHEMBL_ACT_7691959 |
| HTR2B | 6.08 | Ki | 828 | nM | CHEMBL_ACT_7691958 |
| DRD1 | 5.96 | AC50 | 1100 | nM | CHEMBL_ACT_25181186 |
| DRD3 | 5.92 | IC50 | 1210 | nM | CHEMBL_ACT_7689810 |
| HTR2B | 5.89 | IC50 | 1301 | nM | CHEMBL_ACT_7691957 |
Target pathways
Aggregated over 4 target gene(s): CHRM1, CHRM2, CHRM3, CHRM4.
Top Reactome pathways
17 total, by targets touching each:
| Pathway | Targets | Genes |
|---|---|---|
| Signal Transduction | 4 | CHRM1, CHRM2, CHRM3, CHRM4 |
| Signaling by GPCR | 4 | CHRM1, CHRM2, CHRM3, CHRM4 |
| Class A/1 (Rhodopsin-like receptors) | 4 | CHRM1, CHRM2, CHRM3, CHRM4 |
| Amine ligand-binding receptors | 4 | CHRM1, CHRM2, CHRM3, CHRM4 |
| GPCR downstream signalling | 4 | CHRM1, CHRM2, CHRM3, CHRM4 |
| Muscarinic acetylcholine receptors | 4 | CHRM1, CHRM2, CHRM3, CHRM4 |
| GPCR ligand binding | 4 | CHRM1, CHRM2, CHRM3, CHRM4 |
| G alpha (q) signalling events | 2 | CHRM1, CHRM3 |
| G alpha (i) signalling events | 2 | CHRM2, CHRM4 |
| Metabolism | 1 | CHRM3 |
| Integration of energy metabolism | 1 | CHRM3 |
| Membrane Trafficking | 1 | CHRM2 |
| Acetylcholine regulates insulin secretion | 1 | CHRM3 |
| Regulation of insulin secretion | 1 | CHRM3 |
| Vesicle-mediated transport | 1 | CHRM2 |
| Cargo recognition for clathrin-mediated endocytosis | 1 | CHRM2 |
| Clathrin-mediated endocytosis | 1 | CHRM2 |
Dominant GO biological processes
| GO term | Targets |
|---|---|
| signal transduction | 4 |
| G protein-coupled receptor signaling pathway | 4 |
| G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger | 4 |
| adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathway | 4 |
| G protein-coupled acetylcholine receptor signaling pathway | 4 |
| chemical synaptic transmission | 4 |
| phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathway | 3 |
| nervous system development | 3 |
| regulation of locomotion | 2 |
| saliva secretion | 2 |
| acetylcholine receptor signaling pathway | 2 |
| regulation of smooth muscle contraction | 2 |
| phospholipase C-activating G protein-coupled receptor signaling pathway | 1 |
| neuromuscular synaptic transmission | 1 |
| positive regulation of monoatomic ion transport | 1 |
Indications & clinical
Indications
1 indication (1 at ChEMBL trial phase 4).
The 1 indication record carries no mapped disease name (EFO/MeSH-only); none shown.
Clinical trials
Total trials: 0.
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.
Related molecules
Related molecules
Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.
566 molecules share ≥1 primary target. Top 60 by shared-target count:
| Molecule | Source | Status | Shared targets |
|---|---|---|---|
| ACLIDINIUM BROMIDE | ChEMBL + PubChem | Phase 4 (approved) | CHRM1, CHRM2, CHRM3, CHRM4 |
| GENTIAN VIOLET | ChEMBL + PubChem | Phase 4 (approved) | CHRM1, CHRM2, CHRM3, CHRM4 |
| Mavorixafor | ChEMBL + PubChem | Phase 4 (approved) | CHRM1, CHRM2, CHRM3, CHRM4 |
| ACETYLCHOLINE | ChEMBL | Phase 4 (approved) | CHRM1, CHRM2, CHRM3, CHRM4 |
| AMIODARONE | ChEMBL | Phase 4 (approved) | CHRM1, CHRM2, CHRM3, CHRM4 |
| AMITRIPTYLINE | ChEMBL | Phase 4 (approved) | CHRM1, CHRM2, CHRM3, CHRM4 |
| AMOXAPINE | ChEMBL | Phase 4 (approved) | CHRM1, CHRM2, CHRM3, CHRM4 |
| ASTEMIZOLE | ChEMBL | Phase 4 (approved) | CHRM1, CHRM2, CHRM3, CHRM4 |
| ATROPINE | ChEMBL | Phase 4 (approved) | CHRM1, CHRM2, CHRM3, CHRM4 |
| BENZTROPINE | ChEMBL | Phase 4 (approved) | CHRM1, CHRM2, CHRM3, CHRM4 |
| BETHANECHOL | ChEMBL | Phase 4 (approved) | CHRM1, CHRM2, CHRM3, CHRM4 |
| BIPERIDEN | ChEMBL | Phase 4 (approved) | CHRM1, CHRM2, CHRM3, CHRM4 |
| CARBACHOL | ChEMBL | Phase 4 (approved) | CHRM1, CHRM2, CHRM3, CHRM4 |
| CARBAMOYLCHOLINE | ChEMBL | Phase 4 (approved) | CHRM1, CHRM2, CHRM3, CHRM4 |
| CEVIMELINE | ChEMBL | Phase 4 (approved) | CHRM1, CHRM2, CHRM3, CHRM4 |
| CHLOROQUINE | ChEMBL | Phase 4 (approved) | CHRM1, CHRM2, CHRM3, CHRM4 |
| CHLORPROMAZINE | ChEMBL | Phase 4 (approved) | CHRM1, CHRM2, CHRM3, CHRM4 |
| CINNARIZINE | ChEMBL | Phase 4 (approved) | CHRM1, CHRM2, CHRM3, CHRM4 |
| CLEMASTINE | ChEMBL | Phase 4 (approved) | CHRM1, CHRM2, CHRM3, CHRM4 |
| CLIDINIUM | ChEMBL | Phase 4 (approved) | CHRM1, CHRM2, CHRM3, CHRM4 |
| CLOMIPRAMINE | ChEMBL | Phase 4 (approved) | CHRM1, CHRM2, CHRM3, CHRM4 |
| CLOTRIMAZOLE | ChEMBL | Phase 4 (approved) | CHRM1, CHRM2, CHRM3, CHRM4 |
| CLOZAPINE | ChEMBL | Phase 4 (approved) | CHRM1, CHRM2, CHRM3, CHRM4 |
| CYCLIZINE | ChEMBL | Phase 4 (approved) | CHRM1, CHRM2, CHRM3, CHRM4 |
| CYPROHEPTADINE | ChEMBL | Phase 4 (approved) | CHRM1, CHRM2, CHRM3, CHRM4 |
| DARIFENACIN | ChEMBL | Phase 4 (approved) | CHRM1, CHRM2, CHRM3, CHRM4 |
| DESLORATADINE | ChEMBL | Phase 4 (approved) | CHRM1, CHRM2, CHRM3, CHRM4 |
| DEXCHLORPHENIRAMINE | ChEMBL | Phase 4 (approved) | CHRM1, CHRM2, CHRM3, CHRM4 |
| DIMENHYDRINATE | ChEMBL | Phase 4 (approved) | CHRM1, CHRM2, CHRM3, CHRM4 |
| DIPHENHYDRAMINE | ChEMBL | Phase 4 (approved) | CHRM1, CHRM2, CHRM3, CHRM4 |
| DIPHENIDOL | ChEMBL | Phase 4 (approved) | CHRM1, CHRM2, CHRM3, CHRM4 |
| DOXEPIN | ChEMBL | Phase 4 (approved) | CHRM1, CHRM2, CHRM3, CHRM4 |
| EBASTINE | ChEMBL | Phase 4 (approved) | CHRM1, CHRM2, CHRM3, CHRM4 |
| ECONAZOLE | ChEMBL | Phase 4 (approved) | CHRM1, CHRM2, CHRM3, CHRM4 |
| FLUPHENAZINE | ChEMBL | Phase 4 (approved) | CHRM1, CHRM2, CHRM3, CHRM4 |
| GLYCOPYRRONIUM BROMIDE | ChEMBL | Phase 4 (approved) | CHRM1, CHRM2, CHRM3, CHRM4 |
| HALOPERIDOL | ChEMBL | Phase 4 (approved) | CHRM1, CHRM2, CHRM3, CHRM4 |
| HOMATROPINE | ChEMBL | Phase 4 (approved) | CHRM1, CHRM2, CHRM3, CHRM4 |
| HYDROXYCHLOROQUINE | ChEMBL | Phase 4 (approved) | CHRM1, CHRM2, CHRM3, CHRM4 |
| IMIPRAMINE | ChEMBL | Phase 4 (approved) | CHRM1, CHRM2, CHRM3, CHRM4 |
| IPRATROPIUM | ChEMBL | Phase 4 (approved) | CHRM1, CHRM2, CHRM3, CHRM4 |
| KETOTIFEN | ChEMBL | Phase 4 (approved) | CHRM1, CHRM2, CHRM3, CHRM4 |
| LOXAPINE | ChEMBL | Phase 4 (approved) | CHRM1, CHRM2, CHRM3, CHRM4 |
| MAPROTILINE | ChEMBL | Phase 4 (approved) | CHRM1, CHRM2, CHRM3, CHRM4 |
| MEPAZINE | ChEMBL | Phase 4 (approved) | CHRM1, CHRM2, CHRM3, CHRM4 |
| METHSCOPOLAMINE | ChEMBL | Phase 4 (approved) | CHRM1, CHRM2, CHRM3, CHRM4 |
| METHSCOPOLAMINE BROMIDE | ChEMBL | Phase 4 (approved) | CHRM1, CHRM2, CHRM3, CHRM4 |
| MIANSERIN | ChEMBL | Phase 4 (approved) | CHRM1, CHRM2, CHRM3, CHRM4 |
| MICONAZOLE | ChEMBL | Phase 4 (approved) | CHRM1, CHRM2, CHRM3, CHRM4 |
| NORTRIPTYLINE | ChEMBL | Phase 4 (approved) | CHRM1, CHRM2, CHRM3, CHRM4 |
| OLANZAPINE | ChEMBL | Phase 4 (approved) | CHRM1, CHRM2, CHRM3, CHRM4 |
| ORPHENADRINE | ChEMBL | Phase 4 (approved) | CHRM1, CHRM2, CHRM3, CHRM4 |
| OXYBUTYNIN | ChEMBL | Phase 4 (approved) | CHRM1, CHRM2, CHRM3, CHRM4 |
| PAROXETINE | ChEMBL | Phase 4 (approved) | CHRM1, CHRM2, CHRM3, CHRM4 |
| PERHEXILINE | ChEMBL | Phase 4 (approved) | CHRM1, CHRM2, CHRM3, CHRM4 |
| PILOCARPINE | ChEMBL | Phase 4 (approved) | CHRM1, CHRM2, CHRM3, CHRM4 |
| PIRENZEPINE | ChEMBL | Phase 4 (approved) | CHRM1, CHRM2, CHRM3, CHRM4 |
| PROCHLORPERAZINE | ChEMBL | Phase 4 (approved) | CHRM1, CHRM2, CHRM3, CHRM4 |
| PROMAZINE | ChEMBL | Phase 4 (approved) | CHRM1, CHRM2, CHRM3, CHRM4 |
| PROMETHAZINE | ChEMBL | Phase 4 (approved) | CHRM1, CHRM2, CHRM3, CHRM4 |
Related Atlas pages
- Genes: CHRM1, CHRM2, CHRM3, CHRM4
- Drugs: Aclidinium Bromide, Mavorixafor, Acetylcholine, Amiodarone, Amitriptyline, Amoxapine, Astemizole, Atropine, Benztropine, Bethanechol, Biperiden, Carbachol, Cevimeline, Chloroquine, Chlorpromazine, Cinnarizine, Clemastine, Clidinium, Clomipramine, Clotrimazole, Clozapine, Cyclizine, Cyproheptadine, Darifenacin, Desloratadine, Dexchlorpheniramine, Dimenhydrinate, Diphenhydramine, Diphenidol, Doxepin, Ebastine, Econazole, Fluphenazine, Glycopyrronium Bromide, Haloperidol, Homatropine, Hydroxychloroquine, Imipramine, Ipratropium, Ketotifen, Loxapine, Maprotiline, Mepazine, Methscopolamine, Mianserin, Miconazole, Nortriptyline, Olanzapine, Orphenadrine, Oxybutynin, Paroxetine, Perhexiline, Pilocarpine, Pirenzepine, Prochlorperazine, Promazine, Promethazine